1-3 of 3
Sabrina L Garman
Close
Sort by
Journal Articles

The Epstein-Barr Virus Lytic Protein BZLF1 As a Candidate Target Antigen for Vaccine Development

Alex S. Hartlage, Tom Liu, PhD, John T. Patton, Sabrina L Garman, Xiaoli Zhang, PhD MS, Habibe Kurt, MD, Gerard Lozanski, MD, Mark E Lustberg, MD PhD, Michael A. Caligiuri, MD, Robert A. Baiocchi, MD PhD
Journal: Blood
Blood (2014) 124 (21): 4144.
https://doi.org/10.1182/blood.V124.21.4144.4144
Published: 2014
Journal Articles

Serum Mir-29a Is Up-Regulated In Acute Graft Versus Host Disease (aGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) and Activates Dendritic Cells (DCs)

Yvonne A Efebera, MD, Parvathi Ranganathan, Ph.D, Xueyan Yu, Ph.D, Jessica Hofstetter, BS, Sabrina L Garman, BS, Laura Gibson, PhD, William Petros, Michael Craig, MD, Cecelia Fernandez-Cymering, BS, Mehdi Hamadani, MD, Guido Marcucci, MD, Steven M. Devine, MD, Muller Fabbri, MD, Ramiro Garzon, MD
Journal: Blood
Blood (2013) 122 (21): 4471.
https://doi.org/10.1182/blood.V122.21.4471.4471
Published: 2013
Journal Articles

Silvestrol Modulates Direct Anti-Tumor Activity Against Epstein-Barr Virus (EBV)-Associated Lymphomas While Sparing Innate and Antigen Specific Adaptive Immunity

John T. Patton, Mark E Lustberg, MD, PhD, Sabrina L Garman, A Douglas Kinghorn, Ph.D., D.Sc, Li Pan, PhD, David M. Lucas, PhD, Michael R. Grever, M.D., Robert A. Baiocchi, M.D., Ph.D.
Journal: Blood
Blood (2011) 118 (21): 104.
https://doi.org/10.1182/blood.V118.21.104.104
Published: 2011